Hepatitis B (VHB) and C (VHC) are significant global public health issues, particularly for certain risk groups. In the Czech Republic, individuals who inject drugs (IDUs), incarcerated people, and those with high-risk sexual behaviours are especially susceptible. This research investigates the epidemiology, risk factors, and effects of both diseases on these groups. It analyzes the incidence of VHB and VHC in Czechia over the last twenty years in the post-vaccine era, compares their occurrence, and identifies factors influencing their rates. A total of 28,160 VHB and VHC cases reported in the Czech Republic from 2000 to 2021 were analyzed, categorized into acute and chronic forms. Specifically, there were 8,762 cases of VHB and 19,398 cases of VHC. The research employed quantitative methods and descriptive data analysis. A spatial visualization of disease occurrence per 100,000 inhabitants in Czech districts was conducted for the years 2000, 2010, and 2020 to compare disease development and the risk group of IDUs across districts. For VHB, transmission primarily occurs through intravenous drug use or risky sexual behaviour, with IDUs, men who have sex with men, and promiscuous individuals being the most at-risk groups. For VHC, sexual transmission is less common, with IDUs being the most at-risk group. Many VHC cases have been recorded in prisons, often due to shared razors or amateur tattooing and piercing. This discovery underscores the necessity for focused interventions and thorough strategies to address both diseases in high-risk communities.

Department of Epidemiology of Infectious Diseases National Institute of Public Health Prague Czechia

Science and Research Centre Faculty of Health Sciences Palacký University Olomouc Olomouc Czechia

Zobrazit více v PubMed

Ahmad AA, Falla AM, Duffell E, Noori T, Bechini A, Reintjes R, et al. Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries. BMC Infect Dis. 2018;18(1):34. 10.1186/s12879-017-2921-8. PubMed PMC

Brown R, Goulder P, Matthews PC. Sexual dimorphism in chronic hepatitis B virus (HBV) infection: evidence to inform elimination efforts. Wellcome Open Res. 2022;7:32. 10.12688/wellcomeopenres.17601.2. PubMed PMC

Czech Statistical Office. Number of foreigners, demographic events [Internet]. Prague; 2024 [cited 2025 Feb 27]. Available from: https://csu.gov.cz/number-of-foreigners-demographic-events?pocet=10&start=0&podskupiny=291&razeni=-datumVydani#data-and-time-series

Day E, Broder T, Bruneau J, Cruse S, Dickie M, et al. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. Int J Drug Policy. 2019;66:87–93. 10.1016/j.drugpo.2019.01.012. PubMed

European Centre for Disease Prevention and Control. Hepatitis B and C prevention in the EU [Internet]. Stockholm; 2022 [cited 2025 Feb 27]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/hepatitis-B-and-C-prevention-eu-december-2022.pdf

Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries. BMC Infect Dis. 2018;18(1):42. 10.1186/s12879-017-2908-5. PubMed PMC

Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024. https://www.who.int/publications/i/item/9789240091672.

Hejda V. Onemocnění virem hepatitidy C. 1st ed. Prague: Schering-Plough; 2006.

Helcl J, Částková J, Beneš Č, Novotná L, Sepkowitz KA, DeHovitz JA. Control of occupational hepatitis B among healthcare workers in the Czech Republic, 1982 to 1995. Infect Control Hosp Epidemiol. 2000;21(5):343–6. 10.1086/501771. PubMed PMC

Husa P, Šperl J, Urbánek P, Fraňková S, Plíšek S, et al. [Diagnosis and therapy of hepatitis B virus infection: Czech national guidelines]. Klin Mikrobiol Infekc Lek. 2017;23(4):148-64. Czech. PubMed

Jafari S, Buxton JA, Afshar K, Copes R, Baharlou S. Tattooing and risk of hepatitis B: a systematic review and meta-analysis. Can J Public Health. 2012;103(3):207–12. 10.1007/BF03403814. PubMed PMC

Johnson D. Hepatitis transmission risk in nail salons and barbershops and regulatory requirements for prevention: 357. Am J Gastroenterol. 2011;106(Suppl 1):S141.

Karimi-Sari H, Rezaee-Zavareh MS. Altered hepatitis C testing and treatment beyond the COVID-19 pandemic. Public Health. 2022;207: e5. 10.1016/j.puhe.2022.03.018. PubMed PMC

Koroglu M, Demiray T, Ozbek A, Guclu E, Karabay O, et al. Nail scissors and fingernails as reservoirs of hepatitis B virus DNA: role of nail scissors in household transmission of hepatitis B virus. Am J Infect Control. 2018;46(7):793–7. 10.1016/j.ajic.2017.12.009. PubMed

Khetsuriani N, Zaika O, Chitadze N, Slobodianyk L, Allahverdiyeva V, O'Connor P, et al. Seroprevalence of hepatitis B virus infection markers among children in Ukraine, 2017. Vaccine. 2021;39(10):1485–92. 10.1016/j.vaccine.2021.02.004. PubMed PMC

Liu M, Li L, Zhao J, Ungvari GS, Ng CH, et al. Gender differences in demographic and clinical characteristics in patients with HBV-related liver diseases in China. PeerJ. 2022;10: e13828. 10.7717/peerj.13828. PubMed PMC

McAuliffe VJ, Purcell RH, Gerin JL. Type B hepatitis: a review of current prospects for a safe and effective vaccine. Rev Infect Dis. 1980;2(3):470–92. 10.1093/clinids/2.3.470. PubMed

Mitzner SR, Stange J, Klammt S, Koball S, Hickstein H, et al. Albumin dialysis MARS: knowledge from 10 years of clinical investigation. ASAIO J. 2009;55(5):498–502. 10.1097/MAT.0b013e3181b37d86. PubMed

Nguyen TL, Pham TH, So S, Hoang THV, Nguyen TU, Ngo TB, et al. Knowledge, attitudes and practices toward hepatitis B virus infection among students of medicine in Vietnam. Int J Environ Res Public Health. 2021;18(13):7081. 10.3390/ijerph18137081. PubMed PMC

Nguyen VT. Hepatitis B infection in Vietnam: current issues and future challenges. Asia Pac J Public Health. 2012;24(2):361–73. 10.1177/1010539510385220. PubMed

Oliveira AC, Focaccia R. Survey of hepatitis B and C infection control: procedures at manicure and pedicure facilities in São Paulo. Brazil Braz J Infect Dis. 2010;14(5):502–7. 10.1016/S1413-8670(10)70100-8. PubMed

Pley CM, McNaughton AL, Matthews PC, Lourenço J. The global impact of the COVID-19 pandemic on the prevention, diagnosis and treatment of hepatitis B virus (HBV) infection. BMJ Glob Health. 2021;6(1): e004275. 10.1136/bmjgh-2020-004275. PubMed PMC

Rzymski P, Falfushynska H, Fal A. Vaccination of Ukrainian refugees: need for urgent action. Clin Infect Dis. 2022;75(6):1103–8. 10.1093/cid/ciac276. PubMed PMC

Slámová A, Schejbalová M. Epidemiologie virové hepatitidy B se zřetelem na zvláštní očkování [Internet]. Avenier. 2016 [cited 2025 Feb 27]. Available from: https://odbornost.avenier.cz/cz/epidemiologie-virove-hepatitidy-b-se-zretelem-na-zvlastni-ockovani

Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. N Engl J Med. 1984;311(8):496–501. 10.1056/NEJM198408233110803. PubMed

Stránský J. Virová hepatitida B a její klinický význam. Prague: Grada; 2001. ISBN 80-247-0243-6.

Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981;1(5):377–85. 10.1002/hep.1840010502. PubMed

The Lancet Gastroenterology & Hepatology. Eliminating viral hepatitis in the COVID-19 era: weighing challenge and opportunity. Lancet Gastroenterol Hepatol. 2020;5(9):78910.1016/S2468-1253(20)30237-5 PubMed PMC

Tsipotis E, Shuja A, Jaber BL. Albumin dialysis for liver failure: a systematic review. Adv Chronic Kidney Dis. 2015;22(5):382–90. 10.1053/j.ackd.2015.05.004. PubMed

Urbánek P, Husa P, Plíšek S, Rožnovský L. [Standard diagnostic and therapeutic approach to chronic hepatitis C virus (HCV) infection 22 - guidelines]. Klin Mikrobiol Infekc Lek. 2017;23(1):22-40. Czech. PubMed